LU91205I2 - Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) - Google Patents

Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Info

Publication number
LU91205I2
LU91205I2 LU91205C LU91205C LU91205I2 LU 91205 I2 LU91205 I2 LU 91205I2 LU 91205 C LU91205 C LU 91205C LU 91205 C LU91205 C LU 91205C LU 91205 I2 LU91205 I2 LU 91205I2
Authority
LU
Luxembourg
Prior art keywords
alvesco
ciclesonide
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91205C
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of LU91205I2 publication Critical patent/LU91205I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91205C 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) LU91205I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (1)

Publication Number Publication Date
LU91205I2 true LU91205I2 (fr) 2006-05-30

Family

ID=24314964

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
LU91205C LU91205I2 (fr) 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires

Country Status (19)

Country Link
US (1) US5482934A (fr)
JP (1) JP3292928B2 (fr)
KR (1) KR100193085B1 (fr)
AT (1) AT402930B (fr)
AU (1) AU649472B2 (fr)
BE (1) BE1005876A5 (fr)
BR (1) BR1100860A (fr)
CA (1) CA2050812C (fr)
CH (1) CH683343A5 (fr)
DE (2) DE4129535C2 (fr)
ES (1) ES2034893B1 (fr)
FR (1) FR2666585B1 (fr)
GB (1) GB2247680B (fr)
GR (1) GR1001529B (fr)
HK (1) HK1005881A1 (fr)
IT (1) IT1251376B (fr)
LU (2) LU88001A1 (fr)
NL (2) NL194917C (fr)
PT (1) PT98897B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
MY105368A (en) 1990-03-02 1994-09-30 Glaxo Group Ltd Inhalation device.
CZ287877B6 (cs) * 1993-04-02 2001-03-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Prednisolonové deriváty a farmaceutické prostředky s jejich obsahem
WO1995024416A1 (fr) * 1994-03-09 1995-09-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux composes silyle et leur utilisation
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
DE60142920D1 (de) 2000-11-10 2010-10-07 Nycomed Gmbh Verfahren zur herstellung von 16,17-ä(cyclohexylmethylen)bis(oxy)ü -11,21-dihydroxy-pregna-1,4-dien-3,20-dion oder ihre 21-isobutyrat durch transketalisation
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CA2495830C (fr) 2002-08-30 2012-08-21 Altana Pharma Ag Utilisation de la combinaison de ciclesonide et d'antihistaminiques pour le traitement de la rhinite allergique
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
DE602004028497D1 (de) * 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
WO2005025578A1 (fr) * 2003-09-16 2005-03-24 Altana Pharma Ag Utilisation de ciclesonide dans le traitement de maladies respiratoires
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
CA2579007A1 (fr) * 2004-09-10 2006-03-16 Altana Pharma Ag Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
AU2006259604A1 (en) * 2005-06-14 2006-12-28 Gilead Sciences, Inc. Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
KR20080039442A (ko) * 2005-09-02 2008-05-07 니콕스 에스. 에이. 스테로이드 니트록시 유도체들
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
WO2007056181A2 (fr) * 2005-11-02 2007-05-18 Sicor, Inc. Procede perfectionne destine a la preparation de ciclesonide
EP1904514A2 (fr) * 2006-02-08 2008-04-02 Sicor, Inc. Formes cristallines de ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (fr) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Procédé pour préparer le ciclésonide
MX2009000475A (es) 2006-07-19 2009-07-10 Astrazeneca Ab Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
WO2008062450A2 (fr) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Polymorphes cristallins de ciclésonide
EP2064227A2 (fr) 2006-09-19 2009-06-03 Cipla Ltd. Méthodes de préparation de ciclésonide et sa modification cristalline
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
KR20090094460A (ko) 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2022796A1 (fr) * 2007-08-07 2009-02-11 Nycomed GmbH Ciclésonide amorphe
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (fr) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
JP2011513469A (ja) * 2008-03-13 2011-04-28 ファルマビオス ソシエタ ペル アチオニ プレグナン誘導体の製造法
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
US8329729B2 (en) 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
EP2315589A4 (fr) * 2008-05-13 2013-09-11 Astrazeneca Ab PRODUIT PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DU RÉCEPTEUR MUSCARINIQUE ET UN AGONISTE DES béta2-ADRÉNOCEPTEURS
PT2297106E (pt) 2008-05-27 2014-09-29 Astrazeneca Ab Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
ES2471145T3 (es) * 2009-03-09 2014-06-25 Mikasa Seiyaku Co,. Ltd. Compuesto esteroide
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
KR20150043548A (ko) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
WO2011093814A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2011136752A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
WO2013024070A1 (fr) 2011-08-18 2013-02-21 Nycomed Gmbh Produit aérosol pharmaceutique pour l'administration par inhalation orale ou nasale
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
WO2013109212A1 (fr) 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant de la ciclésonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
WO2014007770A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007781A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
EP3250211B1 (fr) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Nouveau procédé de préparation de stéroïdes de type glucocorticoïde
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire
WO2024020164A2 (fr) * 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués
EP4635969A4 (fr) * 2022-12-16 2026-06-10 Tianjin Pharmaceutical Biotechnology Co Ltd Nouveau glucocorticoïde, son procédé de préparation et son utilisation
WO2025085662A1 (fr) 2023-10-17 2025-04-24 Vanderbilt University Composés pour une utilisation tocolytique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378110B (fr) * 1972-05-19 1975-08-18 Bofors Ab
SE378109B (fr) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
AU649472B2 (en) 1994-05-26
US5482934A (en) 1996-01-09
JP3292928B2 (ja) 2002-06-17
FR2666585B1 (fr) 1994-09-09
AT402930B (de) 1997-09-25
IT1251376B (it) 1995-05-09
ES2034893B1 (es) 1994-01-01
NL300196I1 (nl) 2005-08-01
GR910100353A (en) 1992-09-11
ATA176991A (de) 1997-02-15
AU8368691A (en) 1992-03-12
JPH04257599A (ja) 1992-09-11
LU88001A1 (fr) 1992-06-01
PT98897B (pt) 2000-10-31
DE4129535C2 (de) 2001-03-15
HK1005881A1 (en) 1999-01-29
NL194917C (nl) 2003-09-01
KR920006365A (ko) 1992-04-27
BE1005876A5 (nl) 1994-02-22
PT98897A (pt) 1992-07-31
KR100193085B1 (ko) 1999-06-15
ES2034893A1 (es) 1993-04-01
GB2247680B (en) 1994-06-01
GR1001529B (el) 1994-03-31
DE4129535A1 (de) 1992-03-12
FR2666585A1 (fr) 1992-03-13
DE122005000030I2 (de) 2007-12-06
NL300196I2 (nl) 2005-10-03
GB2247680A (en) 1992-03-11
CA2050812C (fr) 2003-07-29
NL9101472A (nl) 1992-04-01
CA2050812A1 (fr) 1992-03-08
BR1100860A (pt) 1999-08-31
DE122005000030I1 (de) 2005-10-06
ITMI912296A0 (it) 1991-08-28
CH683343A5 (de) 1994-02-28
GB9118967D0 (en) 1991-10-23
ITMI912296A1 (it) 1993-02-28

Similar Documents

Publication Publication Date Title
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU90037I2 (fr) Konakion et ses dérivés pharmaceutiquement acceptables
LU91197I2 (fr) Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
FI923677A7 (fi) Foerfarande och anordning foer entydig kombinering av foer en bestaemd behandling avsedda laekemedel med en bestaemd patient
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
BR9101311A (pt) Fralda
FI935920A7 (fi) Oksatsolidiinijohdannaiset ja niiden farmaseuttisesti hyväksyttävät suolat
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FI915855L (fi) Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita
DK0535034T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
OA09840A (fr) dérivés de pipéridine, leur préparation et leur application en thérapeutique
FI930674L (fi) Terapeutiska aemnen